Curr Oncol. 2016 Aug;23(4):e362-8. doi: 10.3747/co.23.3051. Epub 2016 Aug 12.

Prognostic value of pretreatment circulating neutrophils, monocytes, and lymphocytes on outcomes in lung stereotactic body radiotherapy.

Current oncology (Toronto, Ont.)

M Giuliani, L R Sampson, O Wong, J Gay, L W Le, B C J Cho, A Brade, A Sun, A Bezjak, A J Hope

PMID: 27536185 PMCID: PMC4974042 DOI: 10.3747/co.23.3051

Abstract

PURPOSE: In the present study, we determined the association of pretreatment circulating neutrophils, monocytes, and lymphocytes with clinical outcomes after lung stereotactic body radiotherapy (sbrt).

METHODS: All patients with primary lung cancer and with a complete blood count within 3 months of lung sbrt from 2005 to 2012 were included. Overall survival (os) was calculated using the Kaplan-Meier method. Factors associated with os were investigated using univariable and multivariable Cox proportional hazards regression. Fine-Gray competing risk regression was performed to test the association of the neutrophil:lymphocyte (nlr) and monocyte:lymphocyte (mlr) ratios with two types of failure: disease-related failure and death, and death unrelated to disease.

RESULTS: Of the 299 sbrt patients identified, 122 were eligible for analysis. The median and range of the nlr and mlr were 3.0 (0.3-22.0) and 0.4 (0.1-1.9) respectively. On multivariable analysis, sex (p = 0.02), T stage (p = 0.04), and nlr (p < 0.01) were associated with os. On multivariable analysis, T stage (p < 0.01) and mlr (p < 0.01) were associated with disease-related failure; mlr (p = 0.03), nlr (p < 0.01), and sbrt dose of 48 Gy in 4 fractions (p = 0.03) and 54 Gy or 60 Gy in 3 fractions (p = 0.02) were associated with disease-unrelated death. Median survival was 4.3 years in the nlr≤3 group (95% confidence interval: 3.5 to not reached) and 2.5 years in the nlr>3 group (95% confidence interval: 1.7 to 4.8; p < 0.01).

CONCLUSIONS: In lung sbrt patients, nlr and mlr are independently associated with os and disease-unrelated death. If validated, nlr and mlr could help to identify patients who would benefit most from sbrt.

Keywords: hemoglobin; lymphocytes; monocytes; neutrophils; outcomes; sabr; sbrt

References

1. Lancet Oncol. 2015 Jun;16(6):630-7 - PubMed
2. CMAJ. 2009 Jun 23;180(13):1326-8 - PubMed
3. Clin Transl Oncol. 2011 Jul;13(7):499-503 - PubMed
4. J Surg Oncol. 2013 Dec;108(7):481-5 - PubMed
5. Front Oncol. 2012 Aug 24;2:95 - PubMed
6. JAMA. 2010 Mar 17;303(11):1070-6 - PubMed
7. PLoS One. 2014 Jun 26;9(6):e101119 - PubMed
8. Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):1074-81 - PubMed
9. Br J Cancer. 2014 Jul 29;111(3):452-60 - PubMed
10. J Thorac Oncol. 2015 Feb;10(2):280-5 - PubMed
11. Br J Cancer. 2011 Apr 12;104(8):1288-95 - PubMed
12. Semin Cancer Biol. 2013 Jun;23(3):141-8 - PubMed
13. J Lipids. 2014;2014:686791 - PubMed
14. Am J Cardiol. 2006 Apr 1;97(7):993-6 - PubMed
15. Semin Cancer Biol. 2013 Jun;23(3):200-7 - PubMed
16. Oncology. 2007;73(3-4):215-20 - PubMed
17. Radiother Oncol. 2011 May;99(2):161-5 - PubMed
18. Cancer Res. 2010 Jul 15;70(14):5679-85 - PubMed
19. Clin Chem Lab Med. 2015 Jan;53(1):57-64 - PubMed
20. Ann Surg Oncol. 2009 Mar;16(3):614-22 - PubMed
21. Cytokine Growth Factor Rev. 2010 Feb;21(1):3-10 - PubMed
22. Biomarkers. 2012 May;17(3):216-22 - PubMed
23. Br J Cancer. 2013 Jul 23;109(2):416-21 - PubMed
24. Inflammation. 2014 Apr;37(2):374-80 - PubMed
25. J Thorac Oncol. 2015 Jun;10(6):872-82 - PubMed
26. Cell Cycle. 2009 Apr 1;8(7):970-6 - PubMed
27. Cancer. 2015 Feb 15;121(4):545-55 - PubMed
28. Eur Rev Med Pharmacol Sci. 2013 Sep;17(17):2410 - PubMed
29. Transl Cancer Res. 2013 Oct 1;2(5):442-448 - PubMed
30. Hemodial Int. 2014 Jan;18(1):47-53 - PubMed
31. Cancer Metastasis Rev. 2010 Jun;29(2):309-16 - PubMed

Publication Types

• Journal Article